GLP-1 is an FDA-approved treatment that helps regulate appetite, improve metabolism, and support long-term weight management
Continue reading References The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease Food and Drug Administration (FDA) Ozempic Product Label Food and Drug Administration (FDA) Wegovy Product Label FDA Approves Treatment for Serious Liver Disease Known as MASH FDA Press Release: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight Ozempic Tablets Prescribing Information Rybelsus Prescribing Information Wegovy Prescribing Information More about semaglutide Check interactions Compare alternatives Reviews (3,105) Latest FDA alerts (6) Side effects Dosage information Patient tips During pregnancy Support group Drug class: GLP-1 Drugs Breastfeeding Patient resources Other brands Professional resources Other brands Related treatment guides Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
7 UK consensus guidance from the Association of Anaesthetists and the Royal College of Anaesthetists recommends pausing weekly GLP-1 medications, including Wegovy, for 1 week before elective surgery requiring sedation or general anaesthesia
Women over 40 face a metabolic shift that willpower cant fix
Rapid weight loss associated with semaglutide use may lead to changes in skin texture, hydration status, and barrier function
Try: Spacing out meals and snacks across the day Eating slowly and chewing thoroughly Avoiding overly processed or greasy meals, which can trigger nausea or bloating 5
